Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nonavalent HPV vaccination after LEEP for CIN II-III
NL-OMON54737Phase 4Completed
- Sponsor
- Erasmus MC
- Start
- Oct 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in cervical intraepithelial neoplasia (CIN) comparing Nonavalent HPV vaccine with Placebo (2 arms). Primary endpoint: Recurrence of CIN II-III after 24 months. Started Oct 2019; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NL-OMON54737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54737.